Blood Cancer News and Research

RSS

myeloMATCH program opens enrollment for acute myeloid leukemia and MDS

Four leading cancer research organizations in the United States and Canada announce the opening of patient enrollment to myeloMATCH, a unique portfolio of clinical trials to test precision medicine treatments for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

23 Oct 2024

Groundbreaking findings on TET2 pathway open doors for targeted blood cancer treatments

Approximately 30% of individuals with myeloid malignancy diseases have a mutation in a certain gene called tet methylcytosine dioxygenase 2 (TET2).

23 Oct 2024

Unraveling the mechanisms of B-cell maturation in blood cancer

Over four hundred people, 80% of them being children under 14 years old, will be diagnosed with B-cell Acute Lymphoblastic Leukaemia (B-ALL) next year in Spain, according to the latest projections from the Spanish network of cancer registries (REDECAN).

21 Oct 2024

Case Western Reserve University receives grant to investigate AML treatment for veterans

With a new four-year, $1.3 million grant from the U.S. Department of Veterans Affairs, researchers at Case Western Reserve University are investigating a new approach to treat Acute Myeloid Leukemia (AML) in military Veterans.

15 Oct 2024

Epigenetic testing opens new doors for multiple myeloma treatment

Multiple myeloma is a type of blood cancer that appears mainly after the age of sixty. Its incidence, therefore, increases with the aging of the population.

7 Oct 2024

Why children with Down’s syndrome are predisposed to developing leukaemia

The study uncovers mechanisms linking Down syndrome to leukemia, emphasizing the role of oxidative stress and genetic alterations in fetal blood development.

26 Sep 2024

Nearly half of people older adults plan to get the updated COVID-19 vaccine, poll suggests

The newly updated COVID-19 vaccine just arrived in pharmacies and clinics nationwide, and a new poll suggests nearly half of people age 50 and older plan to get it.

23 Sep 2024

Promising antidepressant offers hope for glioblastoma treatment

Glioblastoma is a particularly aggressive brain tumor that at present is incurable. Cancer doctors can extend patients' life expectancy through operations, radiation, chemotherapy or surgical interventions. Nevertheless, half of patients die within twelve months of diagnosis.

20 Sep 2024

Phase 1 trial shows safety and efficacy of personalized vaccine for lymphoplasmacytic lymphoma

A team of researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S., and The University of Texas M.D. Anderson Cancer Center, have reported safety and efficacy results from a Phase 1 trial that featured a personalized vaccine to treat lymphoplasmacytic lymphoma, a rare and slow-growing type of blood cancer, according to a study published recently in Nature Communications.

19 Sep 2024

Multiple myeloma drug shows efficacy in treating rare bleeding disorder

A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder.

19 Sep 2024

UC's Eric Vick receives major grants to advance research into combination therapy for leukemia

The University of Cincinnati Cancer Center's Eric Vick, MD, PhD, has been awarded a nearly $215,000 Career Development Award from the Leukemia and Lymphoma Society (LLS) and a $50,000 American Society of Clinical Oncology (ASCO) Young Investigator Award to continue research into a combination therapy treatment for acute myeloid leukemia (AML).

6 Sep 2024

Clonal hematopoiesis drives femoral atherosclerosis in middle-aged adults

Researchers reveal that clonal hematopoiesis (CH) significantly increases the risk of developing femoral atherosclerosis, suggesting a unidirectional relationship independent of traditional cardiovascular risk factors.

2 Sep 2024

Quality-of-life measurements are essential in cancer care, study says

As novel cancer treatments continually emerge, it is essential to collect data on patients' quality of life along with how the treatment is working to extend survival.

5 Aug 2024

FDA grants accelerated approval for first engineered T cell therapy to treat adults with synovial sarcoma

The U.S. Food and Drug Administration (FDA) has granted accelerated approval for the immunotherapy afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for the treatment of adults with a rare soft tissue cancer called synovial sarcoma.

2 Aug 2024

Using advanced CRISPR to boost efficiency of CAR-T cell therapies

CAR-T cells are highly effective in treating selected blood cancers. However, challenges remain with this new therapy, which was first approved in 2017 in the USA and a year later in Europe for treating acute lymphoblastic leukemia (ALL).

2 Aug 2024

Simple blood test may predict CAR-T therapy success in multiple myeloma

A simple blood test that measures the number of lymphocytes, a type of white blood cell in the body, may predict whether people who have relapsed multiple myeloma are going to respond well to CAR-T immunotherapy, according to new research from Weill Cornell Medicine, NewYork-Presbyterian, Columbia University and Icahn School of Medicine at Mount Sinai.

24 Jul 2024

$Novel therapy can improve the prognosis of relapsed/refractory acute myeloid leukemia$

Novel therapy can improve the prognosis of relapsed/refractory acute myeloid leukemia

Relapsed/refractory acute myeloid leukemia (AML), a so-called blood cancer, has an extremely poor prognosis because of resistance to anti-cancer drugs and frailty of the patient's organ functions.

18 Jul 2024

Blood cancer drug could help improve the efficiency of radiotherapy in meningiomas

Drugs developed to fight blood and other cancers could also help improve the efficiency of radiotherapy in the most commonly diagnosed low-grade brain tumour in adults, a new study has found.

10 Jul 2024

Regular IgG monitoring and replacement therapy reduce severe infections in CLL and NHL patients

Patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHLs) who received frequent tests for immunoglobulin G (IgG) were less likely to experience severe infections compared with those who didn't, according to a study published in Blood Advances.

21 Jun 2024

Artificial variants of Withanolides act highly specifically against leukemia cells

Nightshade plants produce a diverse array of compounds with therapeutic potential. Researchers at CeMM have now identified an artificial variant inspired by the Withanolides group that acts highly specifically against leukemia cells.